Avalo Therapeutics Future Growth

Future criteria checks 0/6

Avalo Therapeutics's revenue and earnings are forecast to decline at 98.3% and 0.08% per annum respectively while EPS is expected to grow by 53% per annum.

Key information

-0.08%

Earnings growth rate

53.0%

EPS growth rate

Biotechs earnings growth	42.3%
Revenue growth rate	-98.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	19 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:C6K0 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-55	N/A	-47	3
12/31/2025	N/A	-53	N/A	-45	3
12/31/2024	0	-132	N/A	-44	3
9/30/2024	1	-8	-37	-37	N/A
6/30/2024	1	-19	-32	-32	N/A
3/31/2024	1	-49	-27	-27	N/A
12/31/2023	2	-32	-31	-31	N/A
9/30/2023	2	-33	-32	-32	N/A
6/30/2023	17	-25	-19	-19	N/A
3/31/2023	17	-30	-21	-21	N/A
12/31/2022	18	-42	-27	-27	N/A
9/30/2022	17	-51	-40	-40	N/A
6/30/2022	4	-72	-62	-62	N/A
3/31/2022	6	-76	-69	-69	N/A
12/31/2021	5	-84	-71	-71	N/A
9/30/2021	7	-81	-68	-68	N/A
6/30/2021	6	-77	-64	-64	N/A
3/31/2021	4	-73	-53	-53	N/A
12/31/2020	7	-64	-41	-41	N/A
9/30/2020	6	-54	-28	-28	N/A
6/30/2020	7	-44	-24	-24	N/A
3/31/2020	7	-33	-22	-22	N/A
12/31/2019	7	-16	-19	-19	N/A
9/30/2019	0	-13	-20	-19	N/A
6/30/2019	2	-35	-13	-12	N/A
3/31/2019	5	-38	-7	-6	N/A
12/31/2018	7	-37	-4	-3	N/A
9/30/2018	16	-42	-4	-4	N/A
6/30/2018	37	2	N/A	16	N/A
3/31/2018	32	6	N/A	15	N/A
12/31/2017	28	8	N/A	13	N/A
9/30/2017	26	13	N/A	11	N/A
6/30/2017	1	-12	N/A	-11	N/A
3/31/2017	2	-13	N/A	-13	N/A
12/31/2016	1	-16	N/A	-15	N/A
9/30/2016	1	-18	N/A	-14	N/A
6/30/2016	1	-13	N/A	-13	N/A
3/31/2016	N/A	-12	N/A	-11	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	N/A	3	N/A	-11	N/A
6/30/2015	N/A	-2	N/A	-16	N/A
3/31/2015	N/A	-3	N/A	-16	N/A
12/31/2014	N/A	-4	N/A	-16	N/A
9/30/2014	N/A	-17	N/A	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: C6K0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: C6K0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: C6K0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: C6K0's revenue is expected to decline over the next 3 years (-98.3% per year).

High Growth Revenue: C6K0's revenue is forecast to decline over the next 3 years (-98.3% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if C6K0's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 02:45
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avalo Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julian Harrison	BTIG
Louise Chen	Cantor Fitzgerald & Co.
Raghuram Selvaraju	H.C. Wainwright & Co.

Avalo Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

Recent updates

Avalo Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Stockholders' Equity Requirement

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$1.38 loss in 2Q 2022)

New minor risk - Insider selling

New major risk - Revenue and earnings growth

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought €52k worth of stock

Insider recently bought €83k worth of stock

Insider recently bought €63k worth of stock

First quarter 2023 earnings released: US$0.85 loss per share (vs US$2.35 loss in 1Q 2022)

Insider recently bought €49k worth of stock

Insider recently bought €131k worth of stock

Full year 2022 earnings released

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

High number of new and inexperienced directors

Forecast to breakeven in 2024

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$2.04 loss in 3Q 2021)

High number of new and inexperienced directors

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

Forecast to breakeven in 2024

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Full year 2020 earnings released: US$0.88 loss per share (vs US$0.28 loss in FY 2019)

Revenue beats expectations

Cerecor Inc. Announces Final Efficacy Data Including 60-Day Mortality from Their Recently Completed Us-Based, Multi-Center (10 Sites)

Cerecor Inc. Appoints Schond L. Greenway as Chief Financial Officer

New 90-day high: €3.56

New 90-day high: €3.16

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

New 90-day high: €2.72

Cerecor Inc. Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS

New 90-day high: €2.26

Cerecor Inc. Announces First Patient Dosed in A Phase 1B Clinical Trial of Cerc-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Inc. Enters into an Amendment to Its Existing License and Supply Agreement with Watson Laboratories, Inc

Cerecor Inc. Appoints Gilla Kaplan, to Its Board of Directors

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts